[Federal Register Volume 62, Number 225 (Friday, November 21, 1997)]
[Notices]
[Pages 62324-62325]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-30613]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Vaccines and Related Biological Products Advisory Committee; 
Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). At least one 
portion of the meeting will be closed to the public.
    Name of Committee: Vaccines and Related Biological Products 
Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA regulatory issues.
    Date and Time: The meeting will be held on December 4, 1997, 12:30 
p.m. to 3:30 p.m.
    Location: Food and Drug Administration, Bldg. 29, conference

[[Page 62325]]

room 121, 8800 Wisconsin Ave., Bethesda, MD. This meeting will be held 
by a telephone conference call. A speaker telephone will be provided in 
the conference room to allow public participation in the meeting.
    Contact Person: Nancy T. Cherry or Denise H. Royster, Center for 
Biologics Evaluation and Research (HFM-21), Food and Drug 
Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-0314, 
or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-
0572 in the Washington, DC area), code 12388. Please call the 
Information Line for up-to-date information on this meeting.
    Agenda: The committee will discuss the intramural scientific 
program of the Laboratory of Enteric and Sexually Transmitted Diseases.
    Procedure: On December 4, 1997, from 12:30 p.m. to 1:15 p.m., and 
2:30 p.m. to 3:30 p.m., the meeting is open to the public. Interested 
persons may present data, information, or views, orally or in writing, 
on issues pending before the committee. Written submissions may be made 
to the contact person by November 26, 1997. Oral presentations from the 
public will be scheduled between approximately 2:30 p.m. and 3:30 p.m. 
Time allotted for each presentation may be limited. Those desiring to 
make formal oral presentations should notify the contact person before 
November 26, 1997, and submit a brief statement of the general nature 
of the evidence or arguments they wish to present, the names and 
addresses of proposed participants, and an indication of the 
approximate time requested to make their presentation.
    Closed Committee Deliberations: On December 4, 1997, from 1:15 p.m. 
to 2:30 p.m., the meeting will be closed to permit discussion where 
disclosure would constitute a clearly unwarranted invasion of personal 
privacy (5 U.S.C. 552b(c)(6)). The meeting will be closed to discuss 
personal information concerning individuals associated with the 
research program.
    FDA regrets that it was unable to publish this notice 15 days prior 
to the December 4, 1997, Vaccines and Related Biological Products 
Advisory Committee meeting. Because the agency believes there is some 
urgency to bring this issue to public discussion and qualified members 
of the Vaccines and Related Biological Products Advisory Committee were 
available at this time, the Commissioner concluded that it was in the 
public interest to hold this meeting even if there was not sufficient 
time for the customary 15-day public notice.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: November 17, 1997.
Michael A. Friedman,
Deputy Commissioner for Operations.
[FR Doc. 97-30613 Filed 11-20-97; 8:45 am]
BILLING CODE 4160-01-F